Dalteparin Sodium

• PALETTE - Trial for personalisation of sepsis treatment in children and adults Pending
  2025-521371-31-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• The Intensive Care Platform Trial (INCEPT) Recruiting
  2024-516208-41-00 Phase IV 5 countries Rigshospitalet
• Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial … Recruiting
  2023-509022-22-00 Phase III 1 country Akershus University Hospital
• DISTINCT: inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hIp or t… Recruiting
  2023-510186-98-00 Phase IV 1 country Academisch Ziekenhuis Leiden
• RIVACAST - RIVAroxaban versus low-molecular weight heparin in patients with lower limb trauma requiring brace or CASTing Recruiting
  2023-509905-62-00 Phase III 1 country Centre Hospitalier Universitaire D'Angers
• Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosis Recruiting
  2022-502426-41-00 Phase III 1 country Institut Gustave Roussy
• Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE Recruiting
  2022-500974-33-00 Phase III 1 country Centre Hospitalier Universitaire De Saint Etienne
• Pre- vs. postoperative thromboprophylaxis for liver resection – a prospective, multicentre, randomized controlled trial (PREPOSTEROUS trial) Recruiting
  2024-519726-20-00 Phase IV 1 country Oslo University Hospital HF
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 Phase II/III 12 countries Anthos Therapeutics Inc.
• Cluster randomised trial of blood thinners Ended
  2022-502402-32-00 Phase IV 1 country Rigshospitalet

Showing 1–10 of 10 trials